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Refractory ascitesAbstract Aim: To evaluate our first four years experience with 71 cases of TIPSS procedures per-
formed in Assiut University Hospital. Patients and methods: Between February 2011 and April
2015, seventy-one patients who underwent TIPSS procedure in Assiut University Hospital were
included in this study. The patients were selected among those suffering from refractory hepatic
ascites and/or recurrent hematemesis due to variceal bleeding. Follow-up duration of our patients
ranged from 3 to 34 months (mean 15.8). Results: The mean age of the patients was 47
± 10.7 years. The technical success rate was 83%. Seventy-five percent of patients with refractory
ascites improved after TIPSS. Reduction of variceal size occurred in 84.6% of patients. The
3 months mortality rate was 8%. Conclusion: Proper pre-procedural investigations and patients
selection are mandatory for practicing TIPSS. BCS is a common cause of technical and clinical fail-
ure of TIPSS, so practicing TIPSS in BCS should be reserved for experts.
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nd/4.0/).1. Introduction
Transjugular intrahepatic porto-systemic shunt (TIPSS) was
described by Josef Rosch in 1969 as a ‘‘radiologic portocavalshunt’’ in the frame of research on transjugular cholangiogra-
phy which had already shifted to research in transjugular por-
tography (1). This type of shunt was introduced into clinical
practice by Rossle et al., in 1988 (2). Nowadays, TIPSS is an
established treatment for the complications of portal hyperten-
sion. It is a creation of an intrahepatic tract between hepatic
and portal veins, shunting the blood away from hepatic sinu-
soids to reduce the portal venous pressure. The use of TIPSS
for the treatment of variceal hemorrhage refractory to
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tory ascites represent 99% of all TIPSS procedures (3). The
indications of TIPSS continuously expanded over the past
years, to include a broader spectrum of clinical situations such
as hepatorenal syndrome, cirrhotic hydrothorax, Budd–Chiari
syndrome, extrahepatic portal vein thrombosis, venoocclusive
disease, and hepato-pulmonary syndrome (4). In this study
we try to evaluate our first four years experience with 71 cases
of TIPS procedures performed in Assiut University Hospital.
2. Patients and methods
Between February 2011 and April 2015, seventy-one patients
who underwent TIPSS procedure in Assiut University Hospi-
tal were included in this study. The patients were selected
among those suffering from refractory hepatic ascites and/or
recurrent hematemesis due to variceal bleeding. All patients
with hematemesis failed to respond to medical and endoscopic
treatment, and all of them had at least two bleeding episodes
after endoscopic treatment. The presence of esophago-gastric
varices was confirmed endoscopically. Also, we included
patients with refractory ascites, lacking response to salt restric-
tion and diuretic therapy, and needed 3 or more therapeutic
paracentesis per month. We excluded patients with the follow-
ing criteria: clinically significant hepatic encephalopathy grade
2 or more, portal vein thrombosis, uncorrectable coagulopathy
(platelets < 40,000, prothrombin concentration < 45%, or
INR> 2), moderate and severe pulmonary hypertension,
serum bilirubin >3.0 mg/dl, large or central hepatoma, con-
gestive heart failure, multiple hepatic cysts, or uncontrolled
systemic infection.
2.1. Pre-procedural evaluation
All cases were subjected to: (a) History taking which included
personal history, detailed medical therapeutic history, and his-
tory of previous interventions such as endoscopic management
of hematemesis, and therapeutic paracentesis (number, vol-
ume, and frequency), (b) general and abdominal examinations,
(c) imaging studies included abdominal ultrasonography, color
doppler evaluation of the portal and hepatic veins, echocardio-
graphy (stressed on evaluation of the ejection fraction and pul-
monary arterial pressure), chest X-ray, tri-phasic CT or MRI
of the liver, (d) upper GIT endoscopy and (e) laboratory inves-
tigations included Liver biochemical, and serological profile
and coagulation parameters, renal functions, blood counts,
serum electrolytes, and thrombophilia studies for pre-
procedural diagnosed Budd–Chiari syndrome (BCS). Panel
of investigations; including hepatitis markers, alpha one antit-
rypsin, ceruloplasmin, serum ferritin, ANA, rectal snip and
liver biopsy were performed to rule out any etiology for cirrho-
sis before diagnosis of cryptogenic cirrhosis.
A multidisciplinary team evaluated all the patients and a
written consent was taken from all patients before the proce-
dure. Large-volume paracentesis was done regularly in patients
with massive ascites a day or two before TIPSS procedure.
2.2. The procedure
All procedures were performed under general anesthesia. The
right internal jugular vein was accessed using ultrasonographicguidance. A 5 F multipurpose curve catheter was placed into
the right hepatic vein for both free and wedged hepatic venog-
raphy (Fig. 1a). Thereafter, a long 10 F sheath was introduced
through the jugular down the right hepatic vein (or IVC in
BCS).
The portal vein was accessed using a TIPSS needle. If the
needle tip was centrally placed in right (Fig. 1), or left
(Fig. 2) main portal branch, we introduced an angled super
stiff wire immediately down the splenic or superior mesenteric
vein. If the needle tip was eccentric in the vein lumen or later-
ally placed needing special negotiation, we tried a 0.035-in.
standard, angled tip hydrophilic wire. Then we exchanged it
with the super stiff wire using a 4 F or 5 F diagnostic catheter.
Thereafter, a pigtail or multi-side-hole straight catheter was
used both for measurement of the portal and systemic pres-
sures, and for doing subtraction portography. If the hepatic
artery or the liver capsule was punctured during trial of portal
vein accessing, we used to do tract embolization with metallic
coils (if available) to avoid internal hemorrhage (Fig. 3).
Tract dilation was performed to the intended diameter of
the shunt. Our standard balloon diameter was 8 mm. In few
cases with highly fibrotic liver, it required initial dilation with
a smaller (4–5-mm) balloon (Fig. 1b) before the introduction
of the 8 mm balloon. The TIPS sheath then was advanced into
the main portal vein several centimeters beyond the site of por-
tal access for proper placement of the stent device (Fig. 1c).
We used self expandable bared metallic stent (Wall-stent,
Boston Scientific). The device was deployed with its upper
end within 1 cm of the hepatic vein-IVC junction and lower
end in the main PV. We used either fluoroscopic landmarks
or angiographic image (during injection of the both the pigtail
catheter and the 10 F sheath simultaneously) for mapping of
the needed stent covering area. Then, we used either a graded
pigtail catheter or special software of the angiography equip-
ment for calculation of the stent length. Either digital road-
mapping or fluoroscopy overlay technique was used to enable
precise positioning of the stent. We post-dilated the stent using
the same balloon that was used for initial tract dilation
(Fig. 1d).
The multi-holes catheter was then reinserted for measure-
ment of the portosystemic gradient (Fig. 1e). We used a target
portal pressure gradient (PPG) 612 mmHg for patients with
variceal bleeding and a gradient 68mmHg for patients with
ascites. If a 10-mm-diameter stent had been placed and the tar-
get portosystemic gradient had not been reached, we used to
re-dilate the stent with a 9- or 10-mm balloon (except patients
with previous encephalopathy).
In cases with BCS (Fig. 4) who had occlusion of all hepatic
veins, we resorted to direct puncture (n= 6) of the IVC down
the right portal vein or portal bifurcation (if intrahepatic). The
needle was passed through the hepatic parenchyma to access
the portal vein under either fluoroscopic or ultrasound guid-
ance. The TIPSS needle was introduced through the IVC 0–
2 cm below the proposed hepatic vein insertion. In cases with
IVC web (Fig. 5), we did not try to recanalize the IVC and
the procedure was stopped (n= 3).
Technical success was defined as successful implantation of
a TIPSS stent connecting the portal venous system to the hep-
atic veins or IVC with significant reduction of the portal pres-
sure gradient. Clinical success meant disappearance of
patients’ clinical problems i.e. no recurrence of hematemesis
and reduction of the amount of ascites.
Fig. 1 Classic TIPS procedure. Right hepatic venography (a); dilatation of the portal entry using a small balloon (b); introduction of the
long sheath in the PV and doing portogram (c); postdilatation of the stent (d); and post-stenting portogram (e).
Fig. 2 Trans-left portal TIPSS. Puncture of the left PV (a); portogram with the catheter in the main PV (b); and post-stenting portogram
(c).
Fig. 3 TIPSS with coiling of capsular puncture tract. Portogram showing filling of the left gastric varices (a); post-dilatation of the stent
and a metallic coil in the false tract (b), and post-stenting portogram showing poor filling of the left gastric varices (c).
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Fig. 4 Budd–Chiari syndrome. Coronal CT image (a); and post-TIPSS portogram (b) showing the stent connecting the portal vein to the
IVC.
Fig. 5 Failed TIPSS of Budd–Chiari syndrome with IVC web. Transjugular (a), and transfemoral (b) inferior vena cavography showing
occlusion of the suprahepatic IVC, non-filling of the hepatic veins, and dilated collaterals.
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Bolus intravenous heparin of 3000 units was given to patients
who have no suspicion of liver capsular puncture or lacerations.
All patients were referred to a specialized liver intensive care
unit. After occurrence of two stent thromboses, we began giving
fractionated heparin subcutaneously for 3 days, and anti-
platelet for 3 months to all patients with good bleeding indices
and without capsular puncture. Intravenous proton pump inhi-
bitor was given for 2 days. Intravenous broad spectrum antibi-
otic was given (cefotaxime sodium or intravenous ciprofloxacin)
for one day before and 3 days after the procedure. All patients
were given a full protection against hepatic encephalopathy
including intravenous L-ornithine N-aspartate, oral lactulose,
and rifaximin or metronidazole. Diuretics were stopped during
the early post-procedural period. We performed therapeutic
paracentesis for patients with marked ascites once or twice
before discharge. Intravenous fluids, plasma or blood were
given according to fluid charts. Early post procedural
ultrasound was routinely performed to detect intraperitonealbleeding, and Doppler Ultrasonography was used to evaluate
shunt patency.
2.4. Later post-procedural visits
All patients were seen after 1–2 weeks then every 3 months
after the procedure. The work-up included the following: (a)
history taking with stress on any disturbance of the conscious
level, number of therapeutic paracentesis needed, development
of hematemesis, and diuretic dose; (b) clinical examination; (c)
imaging studies (ultrasonography, color doppler, and multi-
detector CT in cases with suspected stent dysfunction); (d) lab-
oratory tests (liver functions, renal functions, ascetic fluid
study and full blood picture); and (e) endoscopic evaluation
of variceal grade.
Follow-up duration of our patients ranged from 3 to
34 months (mean duration was 15.8 months). We excluded
the failed cases and early post-procedure deaths from follow-
up. Follow-up was done by out-patient clinical visits, personal
communications and periodic examination of patients’ medical
Fig. 6 Grades of ascites after TIPSS.
Table 2 Response of esophageal varices (OV) to TIPSS.
OV changes (n= 39)
No. %
Disappeared 5 12.8
Decreased 28 71.8
No improvement 6 15.4
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end of our study in April 2015.
3. Results
The ages of the patients ranged from 15 to 70 years. The mean
age was 47 ± 10.7 years. Sixty-two percent of the patients
were males and thirty-eight percent were females. The most
common etiology of cirrhosis in our patients was chronic hep-
atitis C infection (76%), followed by chronic BCS (12.6%)
(Table1). The third cause was cryptogenic cirrhosis occurred
in 10% of the patients. Only one patient had Schistosoma
mansoni chronic infestation that was diagnosed by history,
rectal snip, and biopsy.
The main indication for TIPSS among the patients of this
study was refractory ascites that was found in 42 patients
(59%). The second indication was recurrent variceal bleeding
in 29 patients (41%).
The technical success rate of the procedure was 83%
(59/71). Failure of the procedure occurred in 17% (12/71).
Six out of the first 20 patients had failed trial (50% success
rate). The other 6 failed cases occurred in the next 51 patients
(88.2% success rate). Failure of PV access was encountered in
9 patients. Three of them had BCS disease. Hard track was a
problem that we faced in 2 patients. In these cases we accessed
the portal vein using TIPSS needle and we passed a wire into
the portal vein, but we couldn’t pass a catheter or balloon
due to tough liver tissue and stiff portal vein wall. Massive
hematemesis occurred during the procedure in one patient,
which forced us to terminate the procedure and applied a
Sengstaken–Blakemore tube to stop bleeding. We stopped
the procedure in 3 cases after diagnosis of IVC web, because
we have not enough experience to recanalize the IVC.
The porto-systemic gradient 68 mmHg was achieved in
only 23 (54.8%) patients with refractory ascites. The presence
of mild encephalopathy in many cases prevented us from over-
dilatation of the stent to avoid worsening of encephalopathy.
Seventy-five percent (75%) of patients with refractory ascites
had lesser sonographic grade of ascites, improved quality of
life and needed lower doses of diuretic during the follow-up
(Fig. 6). Ten patients (27.8%) had no ascites at the last
follow-up visit. Nine patients (25%) still had refractory ascites
after stenting. Seven of them (77.7%) had stent dysfunction
(thrombosis or stenosis).
Esophageal varices were detected in 39 patients. Twenty-
nine of them developed repeated hematemesis, and the other
10 patients were detected during routine preprocedural evalu-
ation for TIPSS that was indicated for treatment of refractory
ascites. Reduction of variceal size occurred in 84.6% of
patients on follow-up endoscopy (Table 2). CompleteTable 1 Causes of liver cirrhosis in the study group.
Cause of cirrhosis (n= 71)
No. %
HCV 54 76
Budd–Chiari 9 12.6
Cryptogenic 7 10
Bilharzial 1 1.4disappearance of varices occurred in 12.8% of patients. Four
patients (10.3%) suffered from hematemesis within the first
month after TIPSS. Two of them were found to have gastric
ulcers. The other 2 patients had shunt thrombosis and were
managed by endoscopic band ligation.
Intraprocedural complications included (Table 3) puncture
of the liver capsule in 4 patients and puncture of hepatic artery
in 2 patients. We deployed coils to ensure occlusion of the
parenchymal tract in 4 patients who passed with uneventful
recovery. One of the two patients for whom we did not embo-
lize the tract after capsular puncture developed significant
(about 400 cc) hemoperitonium. He was managed conserva-
tively and the hemoperitoneum resolved within few days.
One patient with refractory ascites suffered from respiratory
embarrassment during recovery from anesthesia. He was trea-
ted successfully with paracentesis of 3 l of ascetic fluid and
endotracheal re-intubation for oxygen administration. Also,
puncture of the biliary tree occurred in 5 patients with no spe-
cial measures taken. The overall rate of TIPSS failure was
30.5% (18/59) of our patients after successful procedure.
Two patients developed stent thrombosis 24 h, and 7 days after
the procedure consequently. The first patient had BCS with
hypercoagulability, and the stent was just flushed with the wall
of the IVC (inadequate stent covering). Most of the stent ste-
noses (56%) occurred during the first 6 months, 33% occurred
after 6–12 months, and only 11% occurred after 1 year. Hepa-
tic encephalopathy was encountered in 16 of successful cases
(27.6%). It was more frequent during the first 3 months after
the procedure (50%) and less frequent during the next three
months (35.6%).
In this study, 2 patients died during the first week after the
procedure. One of them died of acute right sided heart failure
3 days after the procedure, and the other ofmassive unexplained
hematemesis a day after the procedure. The 3 months mortality
rate was 8% (6/71).
Table 3 Complications of TIPSS procedures.
TIPSS complications No. Percent (%)
Procedural complications Of the total cases
 Liver Capsule puncture 4 5.6
 Bile duct puncture 5 7
 Hepatic artery puncture 2 2.8
 Accidental massive hematemesis 1 1.4
Post procedural complications Of successful cases
 Encephalopathy (new or worse) 16 27
 Mild 4 7
 Severe 12 20
 Stent stenosis 18 30.5
 Congestive heart failure 1 1.7
3-months mortality 6 8
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TIPSS creation could be technically difficult and so should
only be performed by a suitably experienced interventional
radiologist (5). The success rate with TIPSS for the decompres-
sion of the portal vein is as high as 90% in most series (6–8). In
this study, the technical success rate was 83.1%. The success
rate increased with time; it was 50% success in the first 20
cases, and reached 88.2% in the next 51 cases. We improved
our skills by: better pre-procedural interpretation of the radio-
logical images, proper selection of the patients, and improve-
ment of our practice with more cautious PV targeting, and
good preparation of the material and equipments of various
sizes, types and different manufacturers.
Therapeutic approaches for patients with the BCS include
medical management, percutaneous or transhepatic angio-
plasty of the narrowed hepatic vein or IVC web (9,10), TIPSS
(11,12), surgical shunts (portal or mesenteric–systemic shunts)
(13,14), and liver transplantation in selected patients. TIPSS
provides instant decompression of both sinusoidal and
splanchnic beds and facilitates arterial perfusion. In these
cases, TIPSS could be performed either by transjugular cavo-
portal shunt, or by transhepatic retrograde approach. In this
study, we did not try IVC web dilatation in three patients,
and we failed to construct TIPSS in another three patients.
Hence, BCS was the most common cause of technical failure.
Many challenges faced us and technical tricks helped us to
overcome these situations. The first trick is the manipulation of
TIPS needle to gain more or less angulations to overcome spa-
tial PV and HV relative orientation. The second is the use of
Cobra catheter instead of MP catheter for catheterization of
acutely angled hepatic vein. The third is the use of hydrophilic
wire to negotiate the PV after its puncture in more lateral posi-
tion. The fourth is the use of small (4 mm) balloon to widen a
hard tract or stiff portal vein wall.
Development of ascites is associated with a poor quality of
life, increased risk of infections and renal failure, and a poor
long-term outcome (15). Cirrhotic patients who develop ascites
have a probability of survival of 85% at 1 year and 56% at
5 years without liver transplantation (16). In patients who
become resistant to diuretic therapy, the prognosis decreases
to 50% survival at 2 years (17). A meta-analysis study was
published in 2005 (18) comparing TIPSS to large volume
paracentesis (LVP) in the treatment of patients with refractorycirrhotic ascites. In the TIPSS groups the percentage (mean
± SD) of patients who showed improvement in their ascites
was 62.0 ± 19.2% while in the LVP groups improvement
was seen in 23.6 ± 18.5% of patients. In another meta-
analysis study published in 2007 (19), TIPSS was more effec-
tive than paracentesis and its use was associated with a signif-
icantly better transplant free survival (TIPS year-1, 63.1%;
year-2, 49.0%; versus LVP year-1, 52.5%; year-2, 35.2%).
Encephalopathy occurred somewhat more frequently in the
TIPSS groups as compared to the LVP groups (39.4
± 20.9% and 22.6 ± 13.9% of patients, respectively).
Many authors (20–22) found that the 1-year survival
for TIPSS patients when the indication was bleeding varices
(48–90%), is similar to those for ascites (48–76%). In one
study, the survival rate was significantly worse when the indi-
cation was refractory ascites compared with variceal bleeding
(23). These differences likely reflect variations in the severity
of liver disease between the different studies. It may be difficult
to establish an absolute value of decompression in patients
with refractory ascites and pre-existing encephalopathy. We
achieved the 8 mmHg PSG in only 54.8% (23/42) of our
patients, treated for refractory ascites. However, 75%
improved after TIPS with lesser sonographic grade of ascites,
and lower doses of diuretics. These data suggest that higher
gradient may be appropriate in such patients to avoid worsen-
ing of encephalopathy.
Two meta-analysis studies were reported in 1999 (24), and
2008 (25) comparing TIPSS to endoscopic therapy. The results
of both studies showed that TIPSS mirrors the results with
surgical shunts, i.e. there is less rebleeding compared to endo-
scopic therapy but at the price of more encephalopathy with-
out an improvement in overall survival. In this study, the
reduction of variceal size (endoscopically) occurred in 84.6%,
and complete disappearance of varices occurred in 12.8% of
patients. Rebleeding after TIPSS occurred in 13.7% of success-
ful cases which is similar to the majority of the previously pub-
lished data with rebleeding rates ranged from 9% to 23% (26).
In a retrospective series (27) of 1750 patients the incidence
of fatal complications (intra-abdominal hemorrhage, lacera-
tion of the hepatic artery or portal vein, and right heart failure)
was 1.7%. In a study included 119 TIPSS procedures, Baldini
et al. (28) stated that the survival rate was 87% at three
months, 74% at one year, and 57% at three years. In this study
we achieved 89.8% survival rate at the first 3 months, and
84.7% at one year which is comparable to that of the litera-
ture. We have only one periprocedural death mostly due to
acute right sided heart failure. All patients with puncture of
the liver capsule or hepatic artery were managed conserva-
tively. We did not embolize the tract with coils in two patients,
and one of them developed hemoperitoneum, reflecting the
importance of tract occlusion with hemostatic device after cap-
sular puncture.
Porto-systemic encephalopathy (PSE) is a very frequent
complication, and certainly constitutes one major drawback
of TIPS, probably the most limiting one in terms of the indica-
tion of TIPS insertion (4). The overall incidence of HE (27.6%)
among our patients was lower than that published (35–55%) in
the previous studies (29,30). It could be due to cautious selec-
tion of patients and avoiding overdilatation of the stent even if
the targeted pressure gradient was not achieved in patient with
previous mild encephalopathy. Fifty percent of PSE occurred
in the first 3 months after TIPSS procedure, and 35.6% during
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fully patent, and portal pressure is lower than 12 mm Hg (4).
In this study, hepatic encephalopathy was significantly higher
in patients with refractory ascites than patients with rebleeding
varices (37% versus 13% respectively), because the former
were cirrhotic patients already in the decompensated phase
of the disease. Most of the episodes of hepatic encephalopathy
were of mild degree (grade I–II), and the most common precip-
itants were diet rich in animal protein and diuretic over-dose.
Thus, dietary restriction of animal proteins, and avoidance
of diuretic overdose are of paramount importance in avoiding
hepatic encephalopathy.
It was reported that up to 70% of patients experience some
degree of TIPS stenosis within the first year (4). In our study, the
incidence of stent stenosis or thrombosis was 31% within
36 months of follow-up. Fifty-five percent were due to shunt
thrombosis during the first 3 months after stenting. Some
authors (30,31) reported that the causes of stent thrombosis
include leakage of bile into the shunt, hypercoagulable syn-
dromes, or inadequate coverage of the TIPS tract with sufficient
stents. Inadequate stent coverage of the tract with subsequent
stent thrombosis was reported in one of our patients with
BCS. However, we didn’t find any relation between bile duct
injury and stent stenosis, as only two of five patients underwent
bile duct puncture, developed late stent stenosis.5. Conclusion
TIPSS is an effective procedure to prevent rebleeding from
varices and decrease the need paracentesis and diuretics in
patients with refractory ascites. Creation of TIPSS ranks
among the more complex interventional techniques; hence,
proper selection of the patients and proper pre-procedural
investigations are mandatory for practicing TIPSS. BCS is a
common cause of technical and clinical failure of TIPSS, so
practicing TIPSS in BCS should be reserved for experts.
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